Qiagen

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) is a global leader in molecular diagnostics and life sciences research tools. Founded in 1984 as a spin-off from a German university, QIAGEN has grown to become one of the world's largest providers of sample preparation and assay technologies for molecular testing.

QIAGEN's products enable customers to extract, purify, and analyze DNA, RNA, and proteins from biological samples. The company offers a wide range of solutions across the molecular testing workflow, from sample preparation to data analysis and interpretation. Key product lines include nucleic acid extraction kits, PCR and digital PCR systems, next-generation sequencing solutions, and bioinformatics software.

Headquartered in Hilden, Germany, QIAGEN employs approximately 6,200 people worldwide and serves over 500,000 customers globally. In 2022, the company generated revenue of USD 2.26 billion. About half of QIAGEN's sales come from molecular diagnostics for clinical applications, with the other half from life sciences research and applied testing markets.

QIAGEN's molecular diagnostic portfolio includes companion diagnostics for personalized medicine, as well as tests for infectious diseases like tuberculosis and Covid-19. The company played a major role in the pandemic response, with 750 million Covid-19 tests containing QIAGEN products. In the life sciences, QIAGEN's technologies are widely used in academic research, pharmaceutical R&D, and forensic applications.

As a leader in its field, QIAGEN is committed to advancing molecular testing technologies to improve human health and scientific research capabilities. The company continues to invest in expanding its product portfolio and geographic presence to drive future growth in the rapidly evolving molecular diagnostics and life sciences markets.